Short answer
RECURSION PHARMACEUTICALS, INC. (RXRX) filed an 8-K current report with the SEC on September 21, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Tempus agreement extended from five to six years, while Recursion loses its convenience-termination right.
RECURSION PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Tempus agreement extended from five to six years, while Recursion loses its convenience-termination right
- Annual license fees reduced to $14M in years three, four, and five from prior amounts up to $42M
- At least $4M of each annual fee must be paid in cash, limiting Recursion’s ability to avoid dilution
- Recursion granted Tempus oncology-only TxFM access for two years for $12M upfront across two $6M installments
- Recursion receives Tempus pathology records with linked clinical data, potentially strengthening oncology model development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RECURSION PHARMACEUTICALS, INC. 8-K filings
Get the next RXRX 8-K as it lands
Follow RXRX for push alerts, or ask the research agent what this filing means.